J. Cancer Mol. 3: 107-112, 2007
[Research
Paper]
Elevation of Serum HSP90alpha Correlated with the Clinical Stage
of Non-Small Cell Lung Cancer
Anjian Xu, Tian Tian, Jia Hao, Jifu Liu, Zhao Zhang, Juanting Hao,
Shanshan Wu, Lingyun Huang, Xueyuan Xiao, and Dacheng He
Key
laboratory of Cell Proliferation and Regulation of Ministry of
Education, Beijing Normal University, Beijing, China [A. Xu, T. Tian, J.
Hao, Z. Zhang, J. Hao, L. Huang, X. Xiao, D. He];
Department of Thoracic Surgery,
General Hospital of Beijing Unit, PLA, Beijing, China [J. Liu, S. Wu]
Abstract:
AIM:
The heat shock protein HSP90alpha, reportedly expressing in cytoplasm,
had been recently detected in serum-free cultured medium (CM) from
fibrosarcoma cells and breast adenocarcinoma cells. The present study
was designed to investigate whether HSP90alpha could be found in the CM
of lung cancer cell lines, and is a sensitive and specific serum
biomarker for the diagnosis and progression of lung cancer.
METHODS:
In the present study, different secretomic
analyses on the two human lung adenocarcinoma cell lines CL1-0 and CL1-5
with low and high metastatic potential, respectively, were performed
using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry. The candidate biomarker was confirmed by
immunoprecipitation and Western blot, and was further analyzed in 224
serum samples including 141 lung cancer, 37 benign pulmonary diseases,
as well as 46 healthy individuals using ELISA assay.
RESULTS:
Six biomarkers were identified, of which HSP90alpha was significantly
up-regulated in the CM of CL1-5 cells. It was found that the levels of
HSP90alpha were specifically elevated in the sera of non-small cell lung
cancer compared with other groups and were progressively increased with
the clinical stage. At the cut-off point 0.535 on the Receiver
Operating Characteristic curve, HSP90alpha could comparatively
discriminate lung cancer from benign lung disease and healthy control
groups with sensitivity 0.817, specificity 0.919 and total accuracy
80.14%.
CONCLUSION:
HSP90alpha may be a potential useful serum biomarker to discriminate
lung cancer from the benign lung diseases and healthy individuals and
the stage of non-small cell lung cancer.
(Keywords:
HSP90alpha; CL1-0; CL1-5; secretome; metastasis)______________________________________________________________________________________________________________
Received
7/18/07; Revised 8/7/07; Accepted 8/8/07.
1Correspondence:
Dr. Xueyuan Xiao or Dr. Dacheng He,
Key Laboratory of Cell Proliferation and Regulation of Ministry of
Education, Beijing Normal University, 19th Xinjiekouwai
Street 100875, Beijing, China. Fax: 86-10-58809729. E-mail:
xuanjian1981@yahoo.com.cn
2Abbreviations:
NSCLC, non-small
cell lung cancer; AD, adenocarcinoma; CM, cultured medium; MALDI-TOF MS,
matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry; PGK1, phosphoglycerate kinase 1; ENOA,
a-enolase;
TPIS, triosephosphate isomerase; G6PI, glucose-6-phosphate isomerase;
LDH-B, L-lactate dehydrogenase B chain; TFA, trifluoroacetic acid; ROC,
Receiver Operating Characteristic; SCLC, small cell lung carcinoma.
Hyperlink to Full Text [PDF
(912 KB)]
|
